All Updates

All Updates

icon
Filter
Partnerships
Cellectis signs investment agreement with AstraZeneca worth up to USD 245 million to develop next-gen therapeutics
Human Gene Editing
Nov 1, 2023
This week:
Product updates
Nintendo ventures into MMOs with new Switch Online game playtest
Metaverse Experience Platforms
Yesterday
Product updates
HP releases texture library for 3D printing with CoreTechnologie 4D Additive
Additive Manufacturing
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Smart Factory
Oct 21, 2024
Product updates
xAI launches API for third-party developers to access Grok models
Foundation Models
Oct 21, 2024
Partnerships
Nava Benefits partners with OpenAI to launch AI-powered benefits assistant
Foundation Models
Oct 21, 2024
Product updates
IBM releases Granite 3.0 AI models for enterprise use
Foundation Models
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Foundation Models
Oct 21, 2024
M&A
Inflection AI acquires Boundaryless for undisclosed sum to accelerate enterprise AI deployments
Foundation Models
Oct 21, 2024
Industry news
News Corp sues Perplexity AI for alleged copyright infringement
Generative AI Applications
Oct 21, 2024
Product updates
Haiper debuts new video generation model
Generative AI Applications
Oct 21, 2024
Human Gene Editing

Human Gene Editing

Nov 1, 2023

Cellectis signs investment agreement with AstraZeneca worth up to USD 245 million to develop next-gen therapeutics

Partnerships

  • Gene editing biotech company Cellectis and AstraZeneca have partnered to accelerate the development of gene editing therapeutics, with a focus on oncology, immunology, and rare diseases.

  • Under the terms of the agreement, Cellectis will receive an initial payment of USD 105 million, including a USD 25 million upfront fee and USD 80 million in equity investment, resulting in a 22% stake in Cellectis. An additional USD 140 million equity investment by AstraZeneca is expected in early 2024, which will result in a 44% stake in Cellectis.

  • The partnership will leverage Cellectis' gene editing technologies and manufacturing capabilities to create novel treatments across 25 exclusive genetic targets, which could result in up to 10 potential products for development. These products may also be eligible for an option fee for an investigational new drug and milestone payments, ranging from USD 70 million to USD 220 million for each candidate, based on progress in development, regulatory approval, and sales. The partnership also aims at expanding AstraZeneca's cell therapy offerings for cancer and advancing genomic medicines for rare diseases.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.